|
Palo Alto, CA, February 2, 2004 — Telik, Inc. (Nasdaq:
TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and
chief executive officer, will present a company update at the Merrill
Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
in New York City on Wednesday, February 4, 2004 at 8:45 a.m. Eastern
time (5:45 a.m. Pacific time). A live webcast of the presentation
will be accessible at Telik’s website, www.telik.com. An
archive of the webcast will be available on the Telik website approximately
24 hours after the presentation through February 11, 2004.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™. Telik’s product candidates were discovered
using its proprietary drug discovery technology, TRAP, which enables
the rapid and efficient discovery of small molecule drug candidates.
Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
